Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Regulus Therapeutics Inc is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 24 staff and has a trailing 12-month revenue of around USD$5 million.
|Latest market close||USD$0.8966|
|52-week range||USD$0.42 - USD$1.74|
|50-day moving average||USD$0.536|
|200-day moving average||USD$0.6531|
|Wall St. target price||USD$1|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.43|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||N/A|
|1 month (2020-12-22)||-36.41%|
|3 months (2020-10-18)||N/A|
|6 months (2020-07-18)||N/A|
|1 year (2020-01-18)||N/A|
|2 years (2019-01-18)||N/A|
|3 years (2018-01-18)||N/A|
|5 years (2016-01-18)||N/A|
|Revenue TTM||USD$5 million|
|Gross profit TTM||USD$-5,517,000|
|Return on assets TTM||-45.03%|
|Return on equity TTM||-507.19%|
|Market capitalisation||USD$24.9 million|
TTM: trailing 12 months
There are currently 932,304 Regulus Therapeutics shares held short by investors – that's known as Regulus Therapeutics's "short interest". This figure is 12.9% up from 826,083 last month.
There are a few different ways that this level of interest in shorting Regulus Therapeutics shares can be evaluated.
Regulus Therapeutics's "short interest ratio" (SIR) is the quantity of Regulus Therapeutics shares currently shorted divided by the average quantity of Regulus Therapeutics shares traded daily (recently around 515085.08287293). Regulus Therapeutics's SIR currently stands at 1.81. In other words for every 100,000 Regulus Therapeutics shares traded daily on the market, roughly 1810 shares are currently held short.
However Regulus Therapeutics's short interest can also be evaluated against the total number of Regulus Therapeutics shares, or, against the total number of tradable Regulus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regulus Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Regulus Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.028% of the tradable shares (for every 100,000 tradable Regulus Therapeutics shares, roughly 28 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regulus Therapeutics.
Find out more about how you can short Regulus Therapeutics stock.
We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.
Regulus Therapeutics's shares were split on a 1:12 basis on 4 October 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.
Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $0.42 up to $1.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 1.9791. This would suggest that Regulus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Everything we know about the Cloopen Group Holding Limited IPO, plus information on how to buy in.
Everything we know about the Decipher Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Proterra IPO, plus information on how to buy in.
Everything we know about the Grab IPO, plus information on how to buy in.
Everything we know about the Deliveroo IPO, plus information on how to buy in.
Everything we know about the Terns Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Angion Biomedica Corp IPO, plus information on how to buy in.
Everything we know about the PurposeBuilt Brands Inc IPO, plus information on how to buy in.
Everything we know about the Vor Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the LumiraDx Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.